Pharmacy

Attending the AMCP Managed Care and Specialty Pharmacy Annual Meeting in Boston April 23 to April 26? Here are our top session recommendations.

A study from the Intermountain Medical Center Heart Institute has shocking findings about certain blood pressure medications and mortality outcomes.

Diabetes drug spending is on the rise, but there are ways to control it.

A new Oliver Wyman study reveals costly findings about Part D beneficiaries enrolled in plans without preferred pharmacy networks.

We know you’re pressed for time, so we’re here to help. Listen to this two-minute podcast for critical takeaways from three of our top articles.

PBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.

Experts weigh in on a recent lawsuit against PBMs, whether similar lawsuits will crop up, and the likely outcomes.

The new global DNA registry could help enable more precise treatments and identify who’s at risk for certain health problems.

A new study shows efforts to reduce prescription opioid use in adults has not curtailed the incidence of pediatric opioid ingestions. Find out why.

Reduce readmissions by focusing on better engagement with patients and improving coordination from inpatient to outpatient settings.

A new report highlights physical, social, and economic challenges of migraine.

UnitedHealthcare will pass on pharmacy discounts directly to some consumers, signaling the next wave of disruption in healthcare, say industry watchers.

There is no cure for HIV, but with proper medical treatment, the disease can be controlled.

The Cigna-Express Scripts deal may signal a move to more vertical and horizontal healthcare deals. Here’s what else it means.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage.

A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.

Eye-opening research by NTT DATA Services sheds light on healthcare consumer satisfaction with virtual versus human agents.

Hospitals are always looking for ways to reduce readmission rates. They may have an unusual ally in a quality control system originally developed in Europe for the manufacturing sector. Read more about it.

Retail drug chain giant Walgreens made a takeover approach to drug distributor AmerisourceBergen. Here’s what industry watchers want you to know about it.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage

John R. Washlick, Buchanan, Ingersoll & Rooney, and expert in healthcare system transactions and market consolidation, talks to Managed Healthcare Executive about healthcare spin-offs, what that means for the future of mergers and acquisitions, and advice for healthcare executives.

A Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.

Here are three strategies to navigate toward next-generation care management and increase member engagement in the process